title: Response to Comment on "SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML".
abstract: Arsenic trioxide chemotherapy cures acute promyelocytic leukemia by inducing the ubiquitylation of an oncogenic fusion protein containing promyelocytic leukemia protein (PML) subsequent to modification of PML by SUMO1 and SUMO2. We proposed that the SUMO switch at Lys(65) of PML enhanced subsequent SUMO2 conjugation to Lys(160) and consequent RNF4-dependent ubiquitylation of PML. Ferhi et al note differences between their experimental system and ours regarding the outcome and mechanisms of SUMO-dependent PML signaling. When confronted by apparently contradictory data, it is appropriate to drill down to where the differences could lie.
authors: Tumor Microenvironment and Cancer Immunology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
authors: Domenico
authors: D
authors: Fasci
authors: Proteomics and Biological Resources, Genentech Research and Early Development, South San Francisco, CA 92056, USA.
authors: Veronica
authors: V
authors: Anania
authors: Proteomics and Biological Resources, Genentech Research and Early Development, South San Francisco, CA 92056, USA.
authors: Jennie
authors: J
authors: Lill
authors: Tumor Microenvironment and Cancer Immunology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. gsalvesen@sbpdiscovery.org.
authors: Guy
authors: G
authors: Salvesen
mesh_terms: D001151:Arsenic; D009687:Nuclear Proteins / Q000235:genetics; D000071156:Promyelocytic Leukemia Protein; D025521:Tumor Suppressor Proteins / Q000235:genetics; D054875:Ubiquitination
chemical_list: D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D025521:Tumor Suppressor Proteins; D001151:Arsenic